KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Gross Margin (2016 - 2025)

Historic Gross Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 56.38%.

  • Teva Pharmaceutical Industries' Gross Margin rose 62200.0% to 56.38% in Q4 2025 from the same period last year, while for Dec 2025 it was 51.8%, marking a year-over-year increase of 30500.0%. This contributed to the annual value of 51.79% for FY2025, which is 30500.0% up from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Gross Margin of 56.38% as of Q4 2025, which was up 62200.0% from 51.43% recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Gross Margin registered a high of 56.38% during Q4 2025, and its lowest value of 43.21% during Q1 2023.
  • Its 5-year average for Gross Margin is 48.55%, with a median of 47.99% in 2021.
  • Its Gross Margin has fluctuated over the past 5 years, first plummeted by -44300bps in 2022, then soared by 86100bps in 2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Gross Margin (Quarter) stood at 50.0% in 2021, then dropped by -9bps to 45.57% in 2022, then rose by 19bps to 54.18% in 2023, then decreased by -7bps to 50.15% in 2024, then rose by 12bps to 56.38% in 2025.
  • Its last three reported values are 56.38% in Q4 2025, 51.43% for Q3 2025, and 50.34% during Q2 2025.